Tysabri's MoA, historical studies on JCV, and early data from patients on Tysabri, suggest association between JCV antibodies and PML but only the larger STRATIFY 2 study will confirm the correlation.
Perhaps the decision is not so horrible if you add switching to Gilenya as an option.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.